Overview

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine treatment will be associated with a decrease in substance use.
Phase:
Phase 4
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
AstraZeneca
Augusta University
Treatments:
Quetiapine Fumarate